Prescription drug · ANDA
Fenofibrate NDC 50268-313
Fenofibrate 160 mg/1 · Tablet · Oral · AvPAK
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50268-313-15 | 50268031315 | 50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-313-15) / 1 TABLET in 1 BLISTER PACK (50268-313-11)Marketed from Aug 13, 2015 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Fenofibrate
- Generic name (nonproprietary)
- fenofibrate
- Active ingredients
- Fenofibrate — 160 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- AvPAKNDC labeler code 50268
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 076509
- Marketing start
- Listing expires
- Identifiers
- Product ID 50268-313_43bf4291-a298-f2fe-e063-6394a90a8fb3SPL ID 43bf4291-a298-f2fe-e063-6394a90a8fb3SPL set ID d4e1d692-3c03-7406-ee06-7a6fb39ed3e7RxCUI 349287, 351133UNII U202363UOS
- Pharmacologic class
- Peroxisome Proliferator Receptor alpha Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450268031315followed by a unit qualifier and the quantityPackage 50268-0313-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. 1.2 Severe Hypertriglyceridemia Fenofibrate tablets are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharm…
Excerpt only. Read the full label for complete information.
About NDC 50268-313
- What is NDC 50268-313?
- 50268-313 is the product NDC for Fenofibrate, Fenofibrate 160 mg/1 tablet, listed with the FDA by AvPAK. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Fenofibrate.
- What is the active ingredient?
- Fenofibrate.
- Who is the labeler?
- AvPAK, NDC labeler code 50268. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Fenofibrate?
- 203 other product NDCs are listed under this name. See all Fenofibrate NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Fenofibrate products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Fenofibrate | Fenofibrate 54 mg/1 | Tablet, Film coatedOral | REMEDYREPACK INC. | 70518-4721 | 70518-4721-00 |
| Fenofibrate | Fenofibrate 145 mg/1 | TabletOral | REMEDYREPACK INC. | 70518-4672 | 70518-4672-00 |
| Fenofibrate | Fenofibrate 145 mg/1 | Tablet, Film coatedOral | Safecor Health, LLC | 48433-040 | 48433-0040-20 |
| Fenofibrate | Fenofibrate 48 mg/1 | Tablet, Film coatedOral | Safecor Health, LLC | 48433-039 | 48433-0039-20 |
| Fenofibrate | Fenofibrate 54 mg/1 | TabletOral | Macleods Pharmaceuticals Limited | 33342-347 | 33342-0347-1033342-0347-1233342-0347-47 |
| Fenofibrate | Fenofibrate 160 mg/1 | TabletOral | Macleods Pharmaceuticals Limited | 33342-348 | 33342-0348-1033342-0348-1233342-0348-15 |
| Fenofibrate | Fenofibrate 145 mg/1 | TabletOral | AvKARE | 73190-016 | 73190-0016-90 |
| Fenofibrate | Fenofibrate 48 mg/1 | TabletOral | AvKARE | 73190-015 | 73190-0015-90 |
| Fenofibrate | Fenofibrate 54 mg/1 | TabletOral | NorthStar RxLLC | 72603-840 | 72603-0840-01 |
| Fenofibrate | Fenofibrate 160 mg/1 | TabletOral | NorthStar RxLLC | 72603-841 | 72603-0841-0172603-0841-02 |
Other NDCs under ANDA 076509
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Fenofibrate | Fenofibrate 54 mg/1 | TabletOral | AvPAK | 50268-312 |
| Fenofibrate | Fenofibrate 160 mg/1 | TabletOral | A-S Medication Solutions | 50090-6974 |
| Fenofibrate | Fenofibrate 160 mg/1 | TabletOral | A-S Medication Solutions | 50090-6973 |
| Fenofibrate | Fenofibrate 160 mg/1 | TabletOral | Northwind Health Company, LLC | 51655-009 |
| Fenofibrate | Fenofibrate 54 mg/1 | TabletOral | Amneal Pharmaceuticals of New York LLC | 0115-5511 |
| Fenofibrate | Fenofibrate 160 mg/1 | TabletOral | REMEDYREPACK INC. | 70518-4326 |
| Fenofibrate | Fenofibrate 160 mg/1 | TabletOral | Amneal Pharmaceuticals of New York LLC | 0115-5522 |
| Fenofibrate | Fenofibrate 160 mg/1 | TabletOral | PD-Rx Pharmaceuticals, Inc. | 72789-410 |
| Fenofibrate | Fenofibrate 54 mg/1 | TabletOral | Amneal Pharmaceuticals LLC | 60219-5511 |
| Fenofibrate | Fenofibrate 160 mg/1 | TabletOral | Amneal Pharmaceuticals LLC | 60219-5522 |